Clinical trials: Heart Failure With Preserved Ejection Fraction (HFPEF)
Heart Failure With Preserved Ejection Fraction (HFpEF)
An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.
This study evaluated the safety and tolerability of LCZ696 treatment in Japanese heart failure patients (NYHA Class II-IV) with preserved ejection fraction after CLCZ696D2301 (PARAGON-HF).
- Trial name
- NCT03909295
- Testing
- LCZ696
- Where
- 17 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Transthyretin Amyloidosis Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia
A multicenter observational retrospective-prospective study of prevalence and clinical characteristics of transthyretin amyloidosis (ATTR) cardiomyopathy (CM) in Russian patients with heart failure with preserved ejection…
- Trial name
- TETRAMER (NCT06338839)
- Where
- 21 sites in Russia
- Volunteers
- 1,770 people
- Sponsor
- AstraZeneca
Heart Failure With Preserved Ejection Fraction
A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT
This is a Phase 2a proof-of-concept study to assess safety, tolerability, and preliminary efficacy of mavacamten treatment on biomarker levels in participants with heart failure with preserved ejection fraction (HFpEF) and…
- Trial name
- EMBARK-HFpEF (NCT04766892)
- Testing
- mavacamten
- Where
- 21 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Bristol-Myers Squibb
Heart Failure With Preserved Ejection Fraction
Diastolic Exercise Stress Testing in Heart Failure
Patients with an intermediate risk (HFA-PEFF score 2-4 points) for heart failure with preserved ejection fraction (HFpEF) will be further investigated with invasive right heart catheterization.
- Trial name
- DEST-HF (NCT04970953)
- Testing
- Right heart catheterization
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- University Hospital, Essen
Heart Failure With Preserved Ejection Fraction (HFpEF), Atrial Fibrillation
Intracranial Pressure and a Potential Vicious Circle of Atrial Fibrillation in HFpEF
This study was designed to investigate predictors of atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFpEF), with a particular focus on the potential relationship between venous…
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF), Atrial Fibrillation, Optic Nerve Sheath Diameter, Intracranial Pressure
- Trial name
- heart failure (NCT07521293)
- Testing
- Echocardiography
- Where
- Turkey (Türkiye)
- Volunteers
- 309 people, healthy volunteers welcome
- Sponsor
- Ankara Ataturk Sanatorium Training and Research Hospital
Heart Failure
Oral Nitrite for Older Heart Failure With Preserved Ejection Fraction
This is a randomized double blinded controlled trial of 20-40 mg sodium nitrite tid in subjects with HFpEF. Primary outcomes are measures of physical function with non-invasive and invasive cardiopulmonary exercise testing, and…
- Trial name
- ONOH (NCT02918552)
- Testing
- sodium nitrite, Control
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Gladwin, Mark, MD
Heart Failure
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.
The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test (6MWT) in patients with chronic heart failure (CHF) with preserved ejection…
- Trial name
- NCT03448406
- Testing
- Empagliflozin
- Where
- 108 sites in United States, Australia and 9 more
- Volunteers
- 315 people
- Sponsor
- Boehringer Ingelheim
Heart Failure with Preserved Ejection Fraction (HFPEF), Heart Failure with Reduced Ejection Fraction
Feasibility and Effectiveness of Eccentric Exercise in Sarcopenic Older Adults with Heart Failure: a Pilot Study
This study is designed to evaluate the safety, feasibility, and effectiveness of a 12-week eccentric exercise program for older adults with sarcopenia (muscle loss) or sarcopenic obesity and chronic heart failure (HF).
- Conditions
- Heart Failure with Preserved Ejection Fraction (HFPEF), Heart Failure with Reduced Ejection Fraction, Sarcopenia in Elderly, Sarcopenic Obesity
- Trial name
- ECLYPSE-HF (NCT06826963)
- Testing
- Aerobic eccentric intervention
- Where
- 2 sites in Italy
- Volunteers
- 15 people
- Sponsor
- Universita di Verona
Heart Failure With Preserved Ejection Fraction
Cilostazol for HFpEF
Determine if cilostazol improves symptoms and NTproBNP levels (heart failure blood marker) in heart failure with preserved ejection fraction (HFpEF) - a prevalent syndrome without targeted evidence-based treatment.
- Trial name
- NCT05126836
- Testing
- Cilostazol 100Mg Tab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Minnesota
Cardiovascular Disease, Cardiometabolic Diseases
Effects of a Specialized Diabetes and Heart Clinic and Detection of Unrecognized Heart Failure in People With Type 2 Diabetes and Cardiovascular Disease
The goal of this clinical trial is to investigate the effects of a specialized Cardio-Metabolic Clinic (CMC) in people with type 2 diabetes and established cardiovascular disease.
- Conditions
- Cardiovascular Disease, Cardiometabolic Diseases, Diabetes Type 2, Diabetes and Heart Failure
- Trial name
- NCT07878325
- Testing
- Cardio-Metabolic Clinic
- Where
- Denmark
- Volunteers
- 375 people
- Sponsor
- Odense University Hospital
Heart Failure With Normal Ejection Fraction
Treatment of HFpEF With Nitrate Supplement
The objective of this project is to determine if Neo40, a nitric oxide generating lozenge, when consumed twice daily by subjects with HFpEF, will increase exercise tolerance, decrease symptoms and improve quality of life for…
- Trial name
- NCT03289481
- Testing
- Active lozenge
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- MaineHealth
Heart Failure With Preserved Ejection Fraction, Beta Blocker
Carvedilol in HF With Preserved EF
Beta-blockers improve clinical outcomes in heart failure and reduced ejection fraction (HFrEF); but not in those with preserved EF.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Beta Blocker, Myocardial Strain
- Trial name
- NCT05553314
- Testing
- Carvedilol
- Where
- 2 sites in South Korea
- Volunteers
- 63 people
- Sponsor
- Seoul National University Bundang Hospital
Heart Failure With Preserved Ejection Fraction (HFPEF), Hemodialysis
The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF
Heart failure is the most common cause of death of patients on chronic hemodialysis treatment, and to date there is no effective therapy for the treatment of this comorbidity in this group of patients.
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFPEF), Hemodialysis, Sacubitril/Valsartan
- Trial name
- NCT07417215
- Testing
- Sacubitril / Valsartan
- Where
- Bosnia and Herzegovina
- Volunteers
- 52 people
- Sponsor
- University Clinical Hospital Mostar
HFpEF - Heart Failure With Preserved Ejection Fraction
Cardiopulmonary Exercise Testing-based High-intensity Interval Training For Improving Heart Failure With Preserved Ejection Fraction
Cardiovascular-Kidney-Metabolic (CKM) Syndrome is a continuous clinical disease spectrum integrating cardiovascular, renal, and metabolic disorders.
- Trial name
- CPHIT-HFpEF (NCT07693049)
- Testing
- High-intensity interval training
- Where
- 13 sites in China
- Volunteers
- 192 people
- Sponsor
- Peking University Third Hospital
Hypertension, Pulmonary, Heart Failure With Normal Ejection Fraction
Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
The primary objective of this study is to Assess the pharmacodynamic profile of riociguat in subjects with symptomatic pulmonary hypertension and heart failure with preserved ejection fraction The secondary objectives of this…
- Trial name
- DYNAMIC (NCT02744339)
- Testing
- Riociguat
- Where
- Austria
- Volunteers
- 118 people
- Sponsor
- Medical University of Vienna
Pulmonary Hypertension Associated With HFpEF
Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF
This was an open-label study to evaluate the safety of continued therapy with oral treprostinil in subjects who completed Study TDE-HF-301.
- Trial name
- NCT03043651
- Testing
- Oral treprostinil
- Where
- 82 sites in United States
- Volunteers
- 48 people
- Sponsor
- United Therapeutics
Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases
Enhancing the Natriuretic Peptide System in HFpEF
The purpose of this study is to look at the differences in how individuals with heart failure with preserved ejection fraction in the presence of chronic kidney disease (HFpEF-CKD) and exercise induced dyspnea without objective…
- Trial name
- NCT05279742
- Testing
- MANP, Sacubitril/Valsartan
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Horng Chen
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Chronic Heart Failure
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure.
- Trial name
- RENEU-HF (NCT06369298)
- Testing
- JK07
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 282 people
- Sponsor
- Salubris Biotherapeutics Inc
Heart Failure Preserved Ejection Fraction
Resistance Training in HFpEF
The objective of this proposal is to determine the effect of resistance exercise training on locomotor muscle function, exercise capacity, exertional symptoms, and quality of life in HF patients with preserved ejection fraction…
- Trial name
- NCT02435667
- Testing
- Resistance Exercise Training, DEXA bone scan, Cardiopulmonary Max Exercise Test
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Heart Failure With Normal Ejection Fraction
Cell Therapy in HFpEF
The primary objective of the study is to investigate safety and efficacy of transendocardial CD34+ cell therapy in patients with HFpEF by evaluating changes in myocardial structure and function, patient exercise capacity and…
- Trial name
- CELLpEF (NCT02923609)
- Testing
- Cell Therapy
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- University Medical Centre Ljubljana